A mechanistic model of erythroblast growth inhibition providing a framework for optimisation of cell therapy manufacturing
Open Access
- 1 May 2018
- journal article
- research article
- Published by Elsevier in Biochemical Engineering Journal
- Vol. 133, 28-38
Abstract
No abstract availableKeywords
Funding Information
- Engineering and Physical Sciences Research Council Fellowship (EP/K00705X/1)
- Wellcome Trust Translational Fund (102610/Z/13/Z)
This publication has 21 references indexed in Scilit:
- Experimentally integrated dynamic modelling for intuitive optimisation of cell based processes and manufactureBiochemical Engineering Journal, 2018
- An immortalized adult human erythroid line facilitates sustainable and scalable generation of functional red cellsNature Communications, 2017
- Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systemsAdvanced Drug Delivery Reviews, 2016
- Computational Modeling of Fed-Batch Cell Culture Bioreactor: Hybrid Agent-Based ApproachIFAC-PapersOnLine, 2015
- Optimal experiment design for nonlinear dynamic (bio)chemical systems using sequential semidefinite programmingAIChE Journal, 2014
- Production of erythrocytes from directly isolated or Delta1 Notch ligand expanded CD34+ hematopoietic progenitor cells: process characterization, monitoring and implications for manufactureCytotherapy, 2013
- Origins and implications of pluripotent stem cell variability and heterogeneityNature Reviews Molecular Cell Biology, 2013
- Model‐based design of experiments for cellular processesWIREs Mechanisms of Disease, 2013
- Nonclinical safety strategies for stem cell therapiesToxicology and Applied Pharmacology, 2012
- Stochastic modelling for quantitative description of heterogeneous biological systemsNature Reviews Genetics, 2009